Terns Pharmaceuticals presented early ASH data showing its targeted chronic myeloid leukemia (CML) drug produced high molecular response rates in heavily pretreated patients. An interim readout reported a 64% major molecular response (MMR) at 24 weeks in 28 evaluable patients, many of whom had received a median of three prior therapies. Company executives positioned TERN‑701 as a potential successor to Novartis’ Scemblix, citing durability and response depth. The findings are preliminary but could shift investor and partner interest if larger trials confirm the signal.